abbvie glp-1 Obesity Late-Comer Inks up to $2.2B Amylin Deal With Gubra AbbVie: stepping up obesity treatments

In addition, the findings still need to be clinically validated, and the specific mechanisms of differentially abundant bacteria or metabolites and lipid metabolism were not explored in depth and need further investigation

Convincing evidence that GLP-1R stimulating drugs are associated with anti-inflammatory, neurotrophic, and neuroprotective properties in preclinical models of NDD has led to trials of these drugs in the NDD clinic

Yu H, Guo P, Xie X, Wang Y, Chen G

Pajares M, Jimnez-Moreno N, Garca-Yage J, Escoll M, de Ceballos ML, Van Leuven F, et al

doi: 10.1002/cnr2.1728 149 Montero-OvalleWSanabria-SalasMCMesa-Lpez de MesaJVarela-RamrezRSegura-MorenoYYSnchez-VillalobosSAet al